Taking people in FranceNo phase
Studies a pump with automatic insulin control in type 1 diabetes
Observes how a Control-IQ insulin pump is used by people with type 1 diabetes.
Key facts
- Who runs it
- Tandem Diabetes Care, Inc.
- Where
- Agen, Angers, Bron, Dijon, Lyon, Mainvilliers, Marseille, Meaux, Metz, Montpellier, Nice, Nîmes, Palavas-les-Flots, Paris, Périgueux, Saint-Cyr-sur-Loire, Strasbourg, Toulouse, and Tours, FranceSee the 25 sites
- Trial code
- Registry title
- The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
- Status
- Recruiting
- People taking part
- 350 people, planned
- Started
- 3 Mar 2026
- Expected to end
- Dec 2027
- Type of study
- Observational
- Treatments tested
- t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
- Record updated
- 14 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with type 1 diabetes in France who have started the t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 or G7 sensor.
- Age
- 6 years or older
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes confirmed by a clinician.
- Earlier treatment
- The clinic has started the t:slim X2 insulin pump with Control-IQ technology and a Dexcom G6 or G7 CGM sensor. People must use an insulin approved for the pump.
Main reasons for not taking part
- A medical condition or medicine that the investigator sees as a safety concern for the study
- People considered vulnerable under French law
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Clinician-confirmed type 1 diabetes and for whom the site has initiated the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with a Dexcom G6 or G7 CGM sensor
- Age ≥ 6 years at enrollment
- Using an insulin approved for use in the pump
- Ability for patient or parent/guardian to respond to alerts and alarms, and to provide basic diabetes self-management
- Reside full-time in mainland France
- Have an email address and mobile phone number
- Participant or participant's parent/guardian has read and understood the information notice and has agreed to participate in the study. This includes agreeing to :; use Control-IQ technology, and to continue use for at least 12 consecutive months after study enrollment; the reuse of their clinical data including HbA1c results, obtained at most 4 months prior to enrollment, and as available according to the standard of care during the next 12 months; complete questionnaires per the study protocol
Who cannot take part
- A medical or other condition, or medications being taken that, in the investigator's judgement would be a safety concern for participation in the study
- Patients considered vulnerable under French law
Where in France
- CH Agen-NéracAgen, FranceContact: Alexandra ByczkoTaking people
- CHU d AngersAngers, FranceContact: Lucie DufourTaking people
- CHU Lyon HFMEBron, FranceContact: Karima RendjaTaking people
- CHU DijonDijon, FranceContact: Eva MichaudTaking people
- Centre du Diabète - Diab-e-Care Hospices Civils de Lyon (HCL)Lyon, FranceContact: Sofia SebaouiTaking people
- Institut de Diabétologie et de Nutrition du Centre (IDNC)Mainvilliers, FranceContact: Said BekkaTaking people
- Hôpital Européen (APHM)Marseille, FranceContact: Audrey OlivettiTaking people
- GHEF MeauxMeaux, FranceContact: Laurence MathivonTaking people
- Chr Metz-ThionvilleMetz, FranceContact: Elodie BersonTaking people
- CHU de MontpellierMontpellier, FranceContact: Manal Al MasriTaking people
- Clinique Saint Jean de VédasMontpellier, FranceContact: Julie SoulierTaking people
- Hopitaux Pediatriques de Nice CHU LenvalNice, FranceContact: Angelika ZieminskiTaking people
- CHU NîmesNîmes, FranceContact: Hasna AllaTaking people
- Institut St-PierrePalavas-les-Flots, FranceContact: Mérédith MercierTaking people
- GH Paris Saint-JosephParis, FranceContact: Nawal AmorTaking people
- Hôpital Européen Georges Pompidou APHPParis, FranceContact: Zahia HadidiTaking people
- Hôpital LariboisièreParis, FranceContact: Djamila BelliliTaking people
- Hopital Robert DebreParis, FranceContact: Caroline Arnaud-SarthouTaking people
- Hôpital St-Antoine (APHP)Paris, FranceContact: Camille VatierTaking people
- CH de PérigueuxPérigueux, FranceContact: Aude AngelescuTaking people
- MSP Les Belles FleursSaint-Cyr-sur-Loire, FranceContact: Magali LecoutreTaking people
- CHRU StrasbourgStrasbourg, FranceContact: Samir ChenafTaking people
- CHU ToulouseToulouse, FranceContact: Laurent CazalsTaking people
- Clinique Pasteur - ToulouseToulouse, FranceContact: Mathilde PistreTaking people
- CHU ToursTours, FranceContact: Sophie GouninTaking people
About the trial
What the trial wants to find out
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
The group in the trial
- Control-IQ System
Participants will use the Control-IQ System as per standard of care.
Treatment: t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
- Plain-language title
- Studies a pump with automatic insulin control in type 1 diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 14 October 2026